Hugo Espinosa
Psychiatry · The Villages, FLNPI 1215194949
Payments from drug & device makers
What this record shows
This record is dominated by other: $62,277 of the $68,809 with a category attached, or 90.5%. Neuronetics, Inc. accounts for 90.9% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $62,605 and has fallen 99.4% since, to $374 in 2025. Among psychiatry clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 71 payments — averaging $969.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuronetics, Inc.$63K
- Alkermes, Inc.$5K
- AbbVie$456
- Otsuka America Pharmaceutical, Inc.$215
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$167
- Lundbeck LLC$157
- plus $688 from 7 others
Across 28 payments — averaging $20,413 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$507K
- Mallinckrodt LLC$65K
What the payments were for
- Consulting fees$4,5007%
- Food & beverage$2,0003%
- Education$320%
- Other$62,27791%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuronetics, Inc. | 5 | $62,527 |
| Alkermes, Inc. | 5 | $4,598 |
| AbbVie(2 entities) | 29 | $456 |
| Otsuka America Pharmaceutical, Inc. | 7 | $215 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $167 |
| Lundbeck LLC | 8 | $157 |
| Briohealth Solutions, Inc. | 1 | $155 |
| Axsome Therapeutics, Inc. | 3 | $137 |
| Corium, LLC | 3 | $137 |
| Neurocrine Biosciences, Inc. | 1 | $125 |
| Vanda Pharmaceuticals Inc. | 2 | $55 |
| Johnson & Johnson | 2 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEUROSTAR TMS THERAPY SYSTEM$62,277
- NEUROSTAR TMS THERAPY$181
- BRIOVAD$155
- INGREZZA$125
- REXULTI$122
- VRAYLAR$114
- CAPLYTA$103
How this compares
$68,809 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 17 | $287 |
| Mirtazapine | 12 | $193 |
| Clonazepam | 16 | $137 |
| Trazodone Hcl | 12 | $51 |
| Buspirone Hcl | 13 | $42 |
| Lorazepam | 12 | $40 |
| Fluoxetine Hcl | 12 | $22 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in The Villages
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
- Todd BroderSt Augustine$1.6M
- Heather LuingSaint Augustine$1.5M
- Todd GatesWest Melbourne$1.2M
- Lawrence ReccoppaGainesville$968K
- Thomas ValenteLeesburg$967K
- Michelle ScargleClearwater$926K
- David SheehanTampa$631K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.